Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy Signal of TP-317 in Patients With Active Ulcerative Colitis

NCT07834515 is registered in ClinicalTrials.gov with Thetis Pharmaceuticals LLC as lead sponsor.

NCT NCT07834515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07834515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy Signal of TP-317 in Patients With Active Ulcerative Colitis
Lead sponsor
Thetis Pharmaceuticals LLC
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 16, 2026
Completion date
August 29, 2027
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis (uc)